Resolution of COVID-19 induced anosmia following treatment with ST266.
Otolaryngol Case Rep
; 25: 100475, 2022 Nov.
Article
in English
| MEDLINE | ID: covidwho-2008186
ABSTRACT
Background:
Persistent anosmia following COVID-19 disease affects a significant subset of patients. Symptoms of this olfactory dysfunction negatively impact patient quality of life, and effective treatments are lacking; therefore, novel therapies that restore the ability to smell have tremendous clinical potential. Case report A 46-year-old female enrolled in a phase I clinical trial to assess the safety of targeted intranasal administration of a novel acellular secretome therapy (ST266) in patients diagnosed as glaucoma suspects. The patient reported greater than one year history of loss of smell that started following a presumed positive case of COVID-19. Following a 28-day treatment course of bilateral intranasal administration of ST266, the patient had resolution of her long-standing anosmia.Conclusion:
This case demonstrates resolution of COVID-19-induced persistent anosmia after intranasal treatment with a novel acellular secretome therapy. Further studies are warranted to determine the potential of ST266 and its components to treat anosmia.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Language:
English
Journal:
Otolaryngol Case Rep
Year:
2022
Document Type:
Article
Affiliation country:
J.xocr.2022.100475
Similar
MEDLINE
...
LILACS
LIS